New York Assembly Bill A09001

New York 2025-2026 Regular Session

• Introduced: 8/13/25
• Refer: 8/13/25
• Refer: 1/7/26
• Report Pass: 2/10/26
• Refer: 2/10/26
• Report Pass: 4/21/26
• Engrossed: 4/27/26
• Refer: 4/27/26

Caption

Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.

Impact

The legislation is expected to have significant implications for state laws concerning drug testing and harm reduction. The commissioner of the Office of Alcoholism and Substance Abuse Services is tasked with overseeing the distribution of these test strips through various facilities, such as hospitals and addiction programs. This distribution aims to ensure accessibility for individuals who might not otherwise have the means or knowledge to verify the safety of their substances. Additionally, by creating a legal framework for these programs, the bill emphasizes the state's commitment to combat the ongoing substance abuse crisis.

Summary

Bill A09001 aims to establish a program within the state of New York that provides individuals with free drug test strips to detect harmful contaminants such as medetomidine, benzodiazepine, and nitazenes. This initiative is a response to the growing concern over the presence of these potent and often dangerous substances in drugs that may be used recreationally. By enabling individuals to test their substances for these contaminants, the bill intends to enhance public health and safety, particularly among populations at higher risk for substance use disorders.

Contention

One notable point of contention surrounding Bill A09001 relates to the potential for its implementation. Critics may raise concerns about perceived encouragement of drug use or the adequacy of public education campaigns accompanying the roll-out of these services. However, proponents argue that providing such resources is vital in reducing harm and preventing overdose deaths. Furthermore, the assurance that individuals seeking these test strips will not face legal repercussions is a crucial aspect of the bill, likely aimed at reducing stigma and fostering a safe environment for those battling substance use issues.